





























Focal segmental glomerulosclerosis (FSGS) is a well-defined pattern of glomerular injury identifiable on renal biopsy 
using light microscopy. FSGS is not a single entity and much information is needed to make a proper evaluation in 
each subject with the condition to identify the cause, prognosticate, and inform treatment choices. Categories of 
information required include: clinical presentation, responsiveness to steroids, pathological subtype, genetic back-
ground, and evidence for other adaptive, viral, and toxic causes. Primary FSGS describes a cohort of conditions 
identified by exclusion of known contributory causes, but does not represent a single entity. Clinical manifestations 
and outcomes of FSGS vary widely; they include asymptomatic proteinuria, cases of spontaneous remission, steroid-
sensitive nephrotic syndrome, and nephrotic syndrome resistant to immune modulating therapy progressing to 
end-stage renal disease with recurrence after transplantation. Although immune modulating therapy (based notably 
on corticosteroids and calcineurin inhibitors) are widely used in primary FSGS, robust evidence of their efficacy 
remains scant.
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INtrODUctION
The term focal segmental glomerulosclerosis (FSGS) 
describes a characteristic pattern of glomerular injury 
which can be identified on light-microscopic (LM) 
examination of renal biopsy material. Glomeruli show 
segmental areas of sclerosis and hyalinosis which may 
progress to global glomerulosclerosis; in progressive 
cases there will also be increasing tubular atrophy and 
interstitial fibrosis. The FSGS pattern was identified by 
light microscopy soon after the introduction of renal 
biopsy into clinical practice in the 1950s. The introduction 
of immunofluorescence (and later immunoperoxidase) 
confirmed the absence of immune deposits (other than 
passive trapping of IgM sometimes seen within sclerotic 
areas). Electron microscopy is unavailable in many parts 
of the world; it is not mandatory for diagnosis but can 
add valuable information: by excluding small immune 
complexes and early amyloid deposition not visible on 
LM or immunofluorescence, by showing glomerular 
basement membrane changes resulting from collagen 
gene mutations which are occasionally associated with 
the FSGS pattern, and by providing an additional esti-
mation of the extent of podocyte injury. 
FSGS was originally associated with nephrotic syndrome 
in children and young adults, in patients who often had 
clinical presentations indistinguishable from those seen 
with minimal change disease (MCD): sudden onset of 
nephrotic syndrome, only manifesting haematuria or 
hypertension in a minority of cases, and with preserved 
glomerular filtration rate (GFR), unless there was marked 
volume depletion associated with the nephrosis. But it 
soon became clear that the FSGS pattern also occurs in 
a far broader range of settings. The condition has been 
increasing in prevalence in all parts of the world where 
there is reliable reporting. In some countries, for example 
Australia, this may reflect a liberal biopsy policy which 
offers biopsy to individuals with asymptomatic protein-
uria as well as those with nephrotic syndrome [1]. But 
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sequential data from Nigeria [2] and United States [3] 
show an increase in the incidence of FSGS; the increase in 
America is especially in those of African origin.  
There has been much progress in our understanding of 
the aetiology and pathogenesis of FSGS, and its recognition 
as a consequence of primary podocyte injury, and new 
treatments are gradually emerging. However, there remain 
a number of issues where clarity is still lacking, and which 
can cause confusion. In this article I discuss some of these 
issues, which include matters of definition and terminology, 
classification, prognostication, and choice of therapy.
DEFINItIONs AND tErMINOLOGY
The terms FSGS and MCD have clear and precise definitions 
of their pathology. But the apparently close relationship 
between FSGS and MCD leaves unresolved the questions 
of whether the two are separate entities, or whether MCD 
can evolve into FSGS. Some pathologists therefore favour 
the inclusive term ‘MCD-FSGS spectrum’. The ‘tip lesion’ 
and ‘collapsing glomerulopathy’ have also been defined 
histologically but controversy still persists about whether 
these are distinct entities or are variants of FSGS. 
Podocytopathy
In an attempt to resolve this lack of clarity, the term 
‘podocytopathy’ has been proposed [4], encompassing a 
variety of histological patterns thought to follow a com-
mon mechanism of primary injury to the podocyte, 
reflecting the rapid increase in our knowledge of podocyte 
pathobiology over the last 20 years. However, the term 
‘podocytopathy’ has not brought the clarity that was hoped 
for. It has often been used loosely to include a wide range 
of podocyte injury, and indeed sometimes to imply only 
podocyte hypertrophy. Proponents of the term ‘podocy-
topathy’ use it to embrace MCD, FSGS, tip lesion, collapsing 
glomerulopathy, and diffuse mesangial sclerosis; but they 
do not include other conditions in which the podocyte 
injury is fundamental to the disease process – be it 
metabolic (as in diabetic nephropathy) or an auto-immune 
process (as in membranous nephropathy). I therefore do 
not favour ‘podocytopathy’ since it seems to add neither 
pathogenic, diagnostic nor therapeutic clarity. 
Idiopathic nephrotic syndrome
Another term best avoided is ‘idiopathic nephrotic 
syndrome’ – which in the past was widely used to bring 
together MCD and FSGS in adults, and steroid-sensitive 
nephrotic syndrome (SSNS) and steroid-resistant nephrotic 
syndrome (SRNS) in children. Use of this term has 
diminished as the aetiology and pathogenesis of FSGS are 
becoming better understood.
steroid responsiveness in nephrotic syndrome
The different clinical approaches to nephrotic syndrome in 
children and adults, while representing sensible pragmatic 
clinical practice, add uncertainty which complicates the 
classification of MCD and FSGS. The great majority of 
those presenting with nephrotic syndrome (adults or 
children), who have a biopsy showing MCD, will be steroid-
sensitive, that is, will have a complete remission of 
proteinuria in response to corticosteroid therapy. It has 
been known, from biopsy studies in children with nephrotic 
syndrome by the International Study of Kidney Disease in 
Children (ISKDC), that the great majority of nephrotic 
children have MCD. This has led to the routine use of 
corticosteroids without renal biopsy for children presenting 
with ‘typical’ nephrotic syndrome, who will mostly prove to 
have SSNS. However, the ISKDC studies showed that not 
all children with MCD are steroid-sensitive. Do such cases 
truly have MCD or is there another histological pattern 
(most commonly FSGS), which would be detected with 
more thorough biopsy analysis? On the other hand, not all 
children with SSNS have MCD, some will have FSGS. 
Resistance to initial steroid therapy defines steroid-resistant 
nephrotic syndrome in children, but this is not synonymous 
with FSGS, since there may be other histological patterns in 
this setting. Although clinical practice guidelines (including 
the KDIGO guideline [5]) recommend that all children 
with SRNS should undergo renal biopsy, this is not always 
done in routine clinical practice, which perpetuates the 
uncertainty about the proportion of those with SRNS who 
have FSGS. In adult practice, initial renal biopsy remains 
the standard approach so that the histological pattern is 
known when therapy is started. These differences in 
practice, and between adults and children, and the 
incomplete correlation between steroid sensitivity and 
histological pattern, have added to our lack of clarity about 
definitions, and present challenges when, for example, 
extrapolating guidance on treatment choices for FSGS in 
adults from data on SRNS in children. 
FsGs as pattern not disease
The FSGS pattern seen on biopsy cannot be attributed to 
a single disease process and may be the consequence of a 
wide range of glomerular insults (Figure 1). These include 
viral infections, medications and toxins, and an adaptive 
response to inherited or acquired reduction in glomerular 
number, genetic susceptibility genes, and genetic mutations 
in podocyte proteins. Terminology is in flux, making the 
older literature hard to interpret. Most use the term 
‘secondary’ FSGS when one or more of these underlying 
causes shown in Figure 1 is identified. ‘Primary’ FSGS is 
typically used to mean those in whom such secondary 
causes are not found. Others prefer the term ‘idiopathic’ 
rather than ‘primary’ FSGS. 
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Clinical and pathological features may be suggestive in 
distinguishing primary from secondary FSGS. Frank 
nephrotic syndrome is more common in primary FSGS, in 
which foot process effacement is typically seen in at least 
80% of glomerular capillary loops visualised on electron 
microscopy. But these are no more than pointers, and no 
substitute for thorough clinical and laboratory evaluation to 
look for underlying causes.
‘Primary’ FsGs
‘Primary’ FSGS is not a single entity. Some cases seem 
closely related to MCD and are steroid-sensitive; some 
may have a circulating factor which is thought to be the 
primary pathogenic mechanism; susceptibility to FSGS and 
its progression may be driven in some by their genetic 
background (see below). More than one of these mecha-
nisms may be present in each case.
The clinical spectrum of primary FSGS includes the 
following: nephrotic syndrome which is fully steroid-
sensitive and never relapses; nephrotic syndrome which 
remits and relapses spontaneously; the clinical entity 
sometimes called ‘malignant FSGS’ [6] which is resistant 
to all immune modulating therapy, causes renal failure in 
months, and relapses immediately in the renal allograft, 
causing early graft failure. Such striking variety in clinical 
patterns argues against a single dominant pathogenic 
mechanism in primary FSGS.
Pathological variants of FsGs
Early work on FSGS described a single characteristic 
morphology. But subsequently other patterns have been 
recognised, and their relationship to FSGS continues to be 
debated. 
tip lesion
In the tip lesion, first described in 1984 [7], there is 
podocyte prominence and capsular adhesion adjacent to 
the urinary pole, with no other segmental sclerotic lesions. 
Nephrotic syndrome is characteristic, with a high chance 
this will be steroid sensitive. Is the tip lesion a variant of 
MCD or a variant of FSGS? Is it a cause or a consequence 
of heavy proteinuria? Given the lack of other glomerular 
injury, and the high rate of steroid sensitivity, some have 
regarded it as a variant of MCD, although it is more com-
monly described as a variant of FSGS. Indirect evidence 
that the tip lesion may be a consequence rather than a 
cause of heavy proteinuria comes from a unique study of 
kidneys from autopsies performed before 1950 in children 
and adults who died of infection with ‘lipoid nephrosis’ (an 
early term encompassing MCD and FSGS). This was in 
the pre-corticosteroid and pre-antibiotic era, so these 
subjects had prolonged nephrotic syndrome. No case 
had pathological features of FSGS, but the majority had 
tip lesions [8].
collapsing glomerulopathy
The characteristic morphology of collapsing glomerulo-
pathy was first described in 1986 [9], and includes 
glomerular tuft collapse with widespread podocyte 
hypertrophy and hyperplasia. Although strongly associated 
with HIV infection in early reports, it also occurs in the 
absence of viral infection or any other apparent cause, and 
is more common in people of African origin. On mor-
phological grounds  collapsing glomerulopathy is usually 
considered a variant of FSGS, though some regard it as a 
separate entity.
Other pathological variants of FsGs
The most widely used classification of pathological features 
in FSGS includes the tip lesion and the collapsing variant. 
It also identifies perihilar and cellular variants of FSGS, 
describing all other cases as FSGS NOS (not otherwise 
specified) [10]. 
Primary FSGS can be associated with FSGS NOS, or tip 
lesion, or the collapsing variant. It has been suggested that 
the perihilar variant may be more commonly seen in 
secondary adaptive FSGS, but uncertainty remains about 
the clinical utility of identifying the perihilar and cellular 
variants, not least because they are uncommon, comprising 
together only 10% of cases from a clinical trial in children 
and young adults with FSGS [11]. 
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Figure 1. secondary FsGs: known associations.
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GENEtIc FActOrs IN FsGs
The importance of genetic susceptibility to FSGS has 
received increasing recognition over recent years. First, 
there are associations with variants in susceptibility genes, 
which increases the risk of developing FSGS. The most 
common example is the APOL1 gene in those of sub-
Saharan African descent. One third of FSGS in the United 
States is associated with APOL1 variants [12]. This is usually 
recessive, requiring two risk alleles, although a report from 
South Africa indicates that a single APOL1 allele is 
associated with HIV-associated nephropathy [13]. Specific 
new therapies may emerge from the current intensive 
study of the molecular pathways of the APOL1 variant 
involved in disease risk.
APOL1 is a susceptibility gene, that is, most patients 
carrying two risk alleles do not get FSGS. This contrasts 
with the other type of genetic FSGS associated with high 
penetrance mutations with Mendelian inheritance. Some 
40 mutations have now been reported affecting podocyte 
proteins (summarised in [14]), and it is highly likely more 
will emerge, as genetic techniques advance. The mutations 
have characteristic age distributions, some strongly asso-
ciated with congenital or very early onset nephrotic 
syndrome, others with clinical onset in later childhood or 
adulthood [15].  
Knowledge of these mutations has mostly emerged from 
the study cohorts including children and young adults with 
SRNS, some of whom have patterns of glomerular injury 
other than FSGS. Many cohorts are also enriched for those 
with a known family history of proteinuria or nephrotic 
syndrome, so there is less certainty about the prevalence of 
mutations in those with apparently sporadic FSGS. Nor 
indeed is the prevalence of these mutations known in SSNS 
or in MCD in adults, since these populations have not 
been systematically studied. Available data suggest that a 
mutation may be found in up to 60% of children presenting 
with SRNS in the first year of life, falling to 10% in the 
second decade of life, and most often in those with a 
known family history [15]. 
There is a debate about the role of mutation testing in the 
evaluation of FSGS in routine clinical care, especially since 
such testing is unavailable or unaffordable in many parts of 
the world – although costs are declining as limited gene 
panels tailored for specific age groups become available. 
Testing in adults can be restricted to those with a family 
history of nephrotic syndrome in whom a mutation is not 
yet identified in another family member. Some argue that 
all children with SRNS should be tested because there 
may be implications for therapy or risk of transplant recur-
rence. A more prevalent view is that testing should only be 
offered for children presenting in the first year of life or 
those with a family history.
tHE rELAtIONsHIP bEtWEEN McD AND 
FsGs, AND bEtWEEN PAtHOLOGIcAL 
PAttErN AND stErOID sENsItIVItY
McD and FsGs
When a case of nephrotic syndrome with a biopsy 
apparently showing MCD proves resistant to cortico-
steroids, the suspicion of unidentified FSGS is raised, and 
a more thorough review of the biopsy or even a repeat 
biopsy is recommended. This is because the focal nature of 
the FSGS lesion, and its initial predilection for deep 
juxtamedullary glomeruli, increase the likelihood that the 
lesions may have been missed especially in small or 
superficial biopsy samples. On the other hand, if an 
individual with nephrotic syndrome and MCD responds 
promptly to corticosteroids, the conventional presumption 
is that the diagnosis is MCD, and the biopsy will not 
be reviewed with such additional rigour, making it uncer-
tain what proportion of those with steroid-sensitive 
‘MCD’ do indeed have FSGS. If a second renal biopsy 
shows FSGS when the first did not, it may be that FSGS 
was missed in the first biopsy but an alternative explana-
tion is that MCD can evolve into FSGS with time. This 
has some support from observations in post-transplant 
recurrence of FSGS, where onset of proteinuria may be 
almost immediate after transplantation. Moreover, a biopsy 
at this stage may show ultrastructural evidence of foot 
process effacement but segmental sclerotic lesions are 
absent and may not appear until weeks or months after 
clinical recurrence.  
 
Pathological pattern and steroid sensitivity
The steroid sensitivity of nephrotic syndrome does not 
map neatly to pathological findings. Not every subject 
with biopsy findings of MCD is steroid-sensitive (though 
steroid-resistant cases might have FSGS which remains 
unidentified because of sampling issues in the biopsy). But 
some cases of FSGS are steroid-sensitive, and subsequently 
behave like MCD, a proportion having multiple relapses. 
Cases of FSGS in which the post-transplant clinical course 
strongly implicates a causative circulating factor are, by 
definition, steroid-resistant since they have developed 
end-stage renal disease (ESRD) despite all therapeutic 
efforts. There are no data to indicate whether some or all 




The failure to identify such a circulating factor unequivo-
cally despite intensive study over more than 20 years 
has been a disappointment. Among recent candidates 
(reviewed in [20]) the most promising was soluble plas-
minogen activating receptor (suPAR) which was initially 
reported to associate strongly with FSGS, but not other 
glomerular diseases. However, more recent studies do 
not confirm its specificity, and suggest that circulating 
suPAR levels are correlated with GFR [21]. The lack of 
a measurable circulating factor means that its possible role 
in the pathogenesis of FSGS outside the specific post-
transplant environment is unknown. Thus, it remains 
unknown what proportion of those with FSGS who are 
steroid-sensitive, or who are steroid-resistant but do not 
progress to ESRD, have a causative circulating factor.
MAKING A cOMPLEtE DIAGNOsIs  
IN FsGs
Physicians value classification of disease because it pro-
vides a framework which is expected to bring clarity and 
accuracy – with positive impacts on precise diagnosis, 
accurate prognosis, and personalised therapy. An 
informative and accurate classification of FSGS has, 
however, proved elusive because of the complexity of 
factors which must be considered.
Pathological findings have dominated thinking about the 
classification of glomerular disease since the introduction of 
renal biopsy in the 1950s. The pathology was soon taken 
to define each ‘disease’. For example both FSGS and 
membranous nephropathy were typically described as 
‘diseases’ even though insights into their aetiology and 
pathogenesis were scanty. An appropriate retreat from 
this position now emphasises that pathological findings 
represent ‘patterns’ not ‘diseases’, and identification of such 
a pattern is the starting point for further evaluation and 
investigation to clarify the diagnosis as precisely as possible. 
Current attempts to classify FSGS typically tabulate the 
factors now known to cause FSGS (Figure 1), and recom-
mend that each case be assigned to one cause – for 
example, adaptive changes to low nephron number, viral 
infection, medications and other toxins, APOL1 poly-
morphisms, or podocyte protein mutations. These various 
entities are together usually called ‘secondary’ FSGS. Such 
‘classification’ has two important limitations. First, it creates 
an unsatisfactory category, ‘primary’ FSGS, which is merely 
a diagnosis by exclusion and is not in any sense a single 
clinicopathological entity. Despite our preference for tidy 
classification, our current understanding of FSGS does 
not allow us to assign cases neatly in this way. For each 
case, at least five domains should be considered and 
described, each of which influences our understanding of 
Initial steroid sensitivity is the single most powerful feature 
in predicting good long-term outcome in FSGS. From the 
patient’s point of view this is what matters, and is much 
more important than the details of the renal biopsy findings, 
which tend to preoccupy nephrologists. Indeed, it could be 
argued that steroid sensitivity should define disease cate-
gories (as has happened for practical operational reasons 
in children) rather than the biopsy findings.  
DOEs PrIMArY FsGs HAVE A sINGLE 
UNIQUE PAtHOGENEsIs?
One justification for the term ’podocytopathy’ was that it 
brings together a group of disorders with common patho-
genesis, even though histological features may vary. Thus, it 
is argued that MCD, tip lesion, FSGS NOS, and collapsing 
glomerulopathy can be considered part of a spectrum with 
genetic factors and glomerular size – itself in part geneti-
cally patterned – influencing the eventual morphological 
and functional manifestations of the disease. Others 
propose that MCD and FSGS have separate pathogenesis, 
but because the podocyte has a limited repertoire of 
responses to injury, they share morphological evidence of 
widespread podocyte injury and the clinical features of 
nephrotic syndrome. Apart from the intellectual challenge 
of resolving this longstanding conundrum, the implications 
for strategies to develop new therapies are important. 
Should a single therapy be sought for a single disease 
mechanism? Or should therapeutic development focus 
separately on MCD and FSGS?
There is inconsistent evidence that MCD and FSGS each 
has unique a podocyte pathobiology. CD80 (B7-1) has 
been one focus of study. An initial report suggested that 
raised urinary CD80 was found in MCD only in relapse 
[16]. A report of increased podocyte CD80 (B7-1) expres-
sion in recurrent FSGS prompted the use of abatacept 
(an anti-B7-1 agent) with anecdotal success in treating 
recurrent FSGS [17]. However, neither the podocyte 
expression variations nor the response to abatacept has 
proved robust in further studies [18]. 
The notion which has received sustained interest is that 
primary FSGS is caused – at least in some cases – by a small 
molecular weight circulating factor. Suggestive clinical 
evidence comes from the immediate recurrence of FSGS 
after transplantation in some subjects, and the prompt 
response of recurrence in many such cases to plasma 
exchange. This is supported by a striking case report of a 
kidney transplanted into a patient with FSGS with imme-
diate recurrence and biopsy evidence of foot process 
effacement; the kidney was removed and transplanted 
into another recipient without FSGS where it functioned 




no relapse; and on the other hand, rapid progression to 
ESRD, and early recurrence after transplant, leaving long-
term dialysis therapy as the only life-sustaining option.
clinical features
Complete remission of nephrotic syndrome is the single 
most powerful predictor of good prognosis, but it should 
not be forgotten that partial remission – variably defined as 
reduction in proteinuria to below the nephrotic range, or 
as halving of the initial proteinuria – also provides significant 
protection against risk of ESRD [22].
For a subject with FSGS who has reduced GFR at pre-
sentation – assuming that it is not due to volume depletion 
or some other reversible consequence of nephrotic 
syndrome – the die is cast, and progression to ESRD is 
highly likely even though skilful care may delay the outcome.
Pathological features
Efforts to use pathological features to assist in prediction of 
outcome have met with mixed success. Most studies show 
that the collapsing variant carries an overall worse prog-
nosis, and the tip lesion a better prognosis than ‘typical‘ 
FSGS. The cellular and perihilar variants have not been 
shown to have prognostic value, although in most series 
these two patterns are too infrequent to exclude their 
relevance with certainty [11]. The possibility of sampling 
error in a focal entity such as FSGS means that caution 
should be exercised in using pathological features, such as 
tubular atrophy and interstitial fibrosis or proportion of 
sclerotic glomeruli, to predict risk and rate of progression.
 
cHOOsING trEAtMENt FOr FsGs
‘Supportive care’ is the term often used for management 
of proteinuric kidney disease with approaches other than 
immunomodulatory therapy. This is applicable to all cases 
with FSGS regardless of the underlying aetiology and 
pathogenesis. The goals of supportive care include tight 
blood pressure control, minimisation of proteinuria and 
reduction of concomitant cardiovascular risk as well as 
specific complications of nephrotic syndrome. ‘Supportive 
care’ includes use of renin-angiotensin system (RAS) 
blockade and other anti-hypertensives with dietary salt 
restriction to maximise their efficacy, diuretics and statins. 
Whether RAS blockade should include ACE inhibitors and 
angiotensin receptor blockers in combination, and the 
possible roles of direct renin inhibitors and aldosterone 
antagonists, are important clinical questions, outside the 
scope of this article. Here I focus on  possible therapeutic 
roles for immune modulating agents – particularly 
corticosteroids, calcineurin inhibitors, and mycophenolate.
the case and its clinical management. The five domains are: 
clinical presentation, pathological subtype, genetic back-
ground, other causative ‘secondary’ features, and steroid 
sensitivity (Figure 2). 
The statement “This patient with FSGS …“ is often heard. 
Nephrologists revert consciously or unconsciously to the 
misunderstanding that it is the pathological pattern which 
defines the disease. While it may be acceptable shorthand, 
it can also betray limitations in understanding the multiple 
domains of any particular case, and indeed of FSGS in 
general. In part, this taxonomic difficulty is understandable 
since it is very difficult conceptually to conflate the five 
domains to express fully the overall understanding of a 
case. It is especially challenging for nephrologists and 
pathologists to synthesise a case and discuss with each 
other when analysis in five dimensions is required. It is even 
more challenging to explain adequately to a patient with 
FSGS and their carers, referring to all five dimensions, the 
complexity of the situation which confronts them.
PrEDIctING PrOGNOsIs IN FsGs
Reliable prediction of prognosis is an important goal for any 
condition in order for the patient and their family to 
understand the implications of the diagnosis and to plan for 
the future, including working with their physician to agree 
on the appropriate therapy. Predicting prognosis becomes 
even more important when the range of possible outcomes 
and their implications are as broad as in FSGS. The possible 
outcomes include, on the one hand, a spontaneous 
remission or a complete response to corticosteroids with 
Figure 2. Domains influencing diagnosis and 
evaluation of FsGs.
A complete and clinically relevant description of each case with 
the FSGS pattern of glomerular injury requires information in 
at least the five domains shown. Only with all this information 
can the management be optimally planned with the patient. 














old. Was secondary FSGS excluded with the rigour 
expected in contemporary clinical practice? Were histo-
logical features defined with the thoroughness used today? 
Were the genetics of the cases defined? Was ‘supportive 
care’ including RAS blockade optimised? Inevitably the 
answer to all these questions in reports from that era 
will be ‘no’. Studies are also confounded by variable defini-
tions of complete, and especially of partial, remission; and 
also by uncertainties about inclusion criteria. Were all 
consecutive cases included? What criteria were used to 
select patients who were not given corticosteroids? Nor is 
there systematic and thorough evaluation of both early and 
late complications of prolonged high dose corticosteroid 
therapy in the early observational studies, limiting the 
opportunity for adequate analysis of risk against benefit.
Another critical issue in justifying the need for prolonged 
corticosteroid therapy is the rate of spontaneous remission 
of nephrotic syndrome in primary FSGS. A substantial 
spontaneous remission rate might cause the treatment 
strategy to be modified. For example, in the absence of 
severe morbid nephrotic syndrome or severe nephrotic 
complications, it might be appropriate to observe pro- 
gress before deciding whether corticosteroid or other 
immune modulating therapy is indeed necessary. 
Studies from the United States have shown spontaneous 
remission rates of 4–6%, whereas one European study 
reported a 16% spontaneous remission (25), and a UK 
study reported 23% [26]. If these higher spontaneous 
remission rates were indeed confirmed, this would shift 
the balance of risk and benefit in deciding if corticosteroids 
are required. A challenge is that the early use of pro- 
longed courses of corticosteroids is so widespread that 
it is now very difficult to establish spontaneous remission 
rates in contemporary practice, or to tell whether resolu-
tion of nephrotic syndrome after four months of corti-




More selective use of corticosteroids depends on the 
extent to which other features of each case can be used 
to predict steroid resistance. Thus, steroid resistance can 
be expected in those with FSGS associated with podo- 
cyte mutations. This might not always be the case, however, 
in those who present in the second or third decade of 
life, since there must be the possibility that a ‘second hit’ 
has allowed clinical expression to emerge, and that this 
second hit might be responsive to steroids. Ancestry is also 
relevant; studies from the US suggest that African Americans 
are less likely to be steroid-responsive.  
Precise diagnosis as emphasised above naturally forms 
the basis for rational choice of therapy. Systematic evidence 
is limited to studies in those with nephrotic syndrome; 
there are almost no data to support a role for immuno-
modulatory therapy in FSGS with subnephrotic proteinuria. 
Most available evidence on immunosuppressive therapy 
comes from studies in those presumed to have primary 
FSGS.
The best available summary of evidence for therapy in 
FSGS is published in the KDIGO clinical practice guideline 
for glomerulonephritis [5]. The guideline summarises all 
studies published up to 2011, and is presently being 
updated. In the KDIGO guideline, separate chapters 
summarise the evidence for treatment of MCD and FSGS 
in adults, and for SSNS and SRNS in children. The evidence 
base for treatment is significantly greater in children; 
there is uncertainty about direct extrapolation between 
SSNS and SRNS in children, and MCD and FSGS, 
respectively, in adults.
corticosteroids
Since the 1950s, corticosteroids have been widely used in 
adults with FSGS. The rationale for their use was never 
clear, other than the observation that the majority of 
those with MCD are steroid-sensitive, and the close 
relationship between MCD and FSGS. It remains unknown, 
67 years after the first reports of the efficacy of corti-
costeroids in childhood nephrotic syndrome (23), why this 
therapy is effective.
There are no RCTs of corticosteroids in FSGS in adults. 
Evidence comes from retrospective cohort studies of 
adults with FSGS and nephrotic syndrome in whom no 
underlying cause was identified and who are therefore 
regarded as having primary FSGS. Initially, these studies 
were from the 1980’s, mostly using oral prednisolone 
typically at 1 mg/kg/day for 8 weeks (based on a typical 
regimen used for SSNS in children). Such studies typically 
report complete remission rates of 20–30%. In the 1990s 
longer durations and higher doses came into favour, notably 
in the United States; up to 4 months of oral prednisolone 
at an initial dose of 1–2 mg/kg was common, and complete 
remission rates of 50–60% were reported [24]. Current 
clinical practice guidelines (including KDIGO) recommend 
this higher dose therapy as immediate initial therapy in 
those presenting with nephrotic syndrome and primary 
FSGS, although the length of time the starting dose is 
maintained before tapering has remained variable.
However, the weaknesses of retrospective observational 
studies as a basis for deciding therapy should not be 
forgotten, especially when the studies are 20 to 30 years 
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Whereas those with the tip lesion are commonly steroid 
sensitive, the collapsing variant has been regarded as 
typically steroid-resistant. However, a recent large retro-
spective study from the US reported a 70% response to 
immunotherapy (corticosteroids or CNI) in collapsing 
FSGS compared to 65% in those with FSGS NOS [27]. 
There were also much higher spontaneous remission rates 
than previously reported from the US: 40% in collapsing 
FSGS with nephrotic syndrome, and 56% in FSGS NOS 
(however, these spontaneous remissions included some 
who were not nephrotic, and among those with nephrotic-
range proteinuria none had serum albumin <33 g/L). 
Although only a retrospective study, these recent data 
nevertheless support the case for a ‘watch and wait’ 
approach in FSGS with nephrotic syndrome (unless the 
patient has severe nephrotic syndrome with complications) 
as recommended for membranous nephropathy.
There are also preliminary reports that altered expression 
of glomerular proteins, including dystroglycan [28], as 
well as variations in glucocorticoid receptor polymor-
phisms [29], may have a role in predicting steroid respon-
siveness, but these require confirmation.
Regrettably, it seems very unlikely that an RCT of 
corticosteroids, in cohorts of FSGS patients carefully 
categorised in the light of current knowledge, which is 
needed to resolve properly these uncertainties, will ever be 
carried out. 
calcineurin inhibitors
A widely used alternative to corticosteroids is calcineurin 
inhibitors (CNI). Again, the rationale is not entirely clear; 
proteinuria reduction by CNI may be due to immuno-
suppressive or non-immunosuppressive effects, the latter 
including haemodynamic effects that reduce GFR and thus 
proteinuria, or direct podocyte effects.
RCTs of cyclosporine – sometimes in combination with 
low dose oral corticosteroids – show partial or complete 
remission rates of 70–75%, although more than half may 
relapse after CNI withdrawal (summarised in [5]). A more 
recent RCT using tacrolimus showed similar efficacy [30]. 
Mycophenolate 
Evidence assessing the role of mycophenolate in FSGS is 
limited. A small RCT comparing a mycophenolate-corti-
costeroid combination with cyclosporine in steroid-resistant 
FSGS showed no difference in remission rates or in the 
maintenance of remission in the six months after stopping 
therapy [31]. Three other small RCTs evaluating myco-
phenolate combined with corticosteroids showed no 
benefit; non-randomised studies in steroid-resistant FSGS 
suggest response rates of 30% or less (reviewed in [32]).
Other treatment options
A range of agents directed at other possible mechanistic 
pathways in FSGS have been evaluated in observational 
studies, or are under investigation in RCTs, but none has 
supportive evidence sufficient to make their use anything 
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